Press Release

Jaguar Health Announces Significant Results in Breast Cancer Patients Accepted for Presentation at Multinational Association of Supportive Care in Cancer (MASCC) Annual Meeting

The statistically significant responder analysis results for Mytesi® (crofelemer) in the Phase 3 OnTarget study's prespecified subgroup of patients with breast cancer were the subject of a December 2024 poster presentation at the San Antonio Breast Cancer Symposium

Late-breaker abstract accepted by MASCC shows additional significant results for breast cancer subgroup

Jaguar planning to meet with FDA in Q2 2025 to discuss possible pathways for crofelemer approval for prophylaxis of diarrhea in patients with breast cancer

A second late-breaker abstract, related to the results of a screening survey of cancer patients about oral mucositis and a follow-up focus group, has also been accepted for presentation at MASCC's 2025 Annual Meeting

Read More